Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important.

@article{Lim2015ValidatingTA,
  title={Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important.},
  author={Andrew B M Lim and Andrew W Roberts and Kate Mason and Ashish Bajel and Jeff Szer and D. Stuart Ritchie},
  journal={Transplantation},
  year={2015},
  volume={99 1},
  pages={128-32}
}
BACKGROUND Reporting allogeneic hematopoietic stem cell transplantation (alloHSCT) outcomes by disease and disease stage can limit statistical power. Recently, the disease risk index (DRI) was developed and validated to stratify clusters of patients with various combinations of disease and stage for overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse (CIR). However, the DRI has not been tested for smaller cohorts or cohorts with shorter follow-up… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 15 references

A class of K-sample tests for comparing the cumulative incidence of a competing risk

  • RJ Gray
  • Ann Stat 1988;16:1141
  • 1988
Highly Influential
2 Excerpts

Comparison of pre-transplant thymoglobulin and post-transplant prednisolone as graft-versus-host disease prophylaxis in matched unrelated donor, peripheral blood stem cell transplantation

  • DS Ritchie, A Lim, E Li
  • Bone Marrow Transplant 2012;47:P533
  • 2012
1 Excerpt

Validation of the haematopoietic cell transplantation-specific comorbidity index: a prospective,multicentreGITMO study

  • R Raimondi, A Tosetto, R Oneto
  • Blood
  • 2012
1 Excerpt

and Marrow Transplant Research analysis

  • ML Sorror, MB Maris, R Storb
  • 2011

Similar Papers

Loading similar papers…